Eli Lilly and Company Canadian Depositary Receipt (ZLLY)

Profile

https://www.lilly.com

Eli Lilly and Company Canadian Depositary Receipt is a structured equity security designed to provide exposure to the common shares of Eli Lilly and Company through a depositary receipt format. It represents an interest in the underlying U.S.-listed pharmaceutical company while trading in a local market currency, typically with features such as a defined share ratio and, in many cases, currency hedging to reduce foreign exchange impact for investors. Eli Lilly and Company is a large global healthcare firm focused on the research, development, and commercialization of prescription medicines, particularly in areas such as diabetes, obesity, oncology, immunology, and neuroscience. The Canadian Depositary Receipt structure allows market participants to access this global blue-chip healthcare exposure using familiar domestic market infrastructure, while still participating in the company’s dividend distributions and corporate actions as passed through by the depositary framework. This instrument plays a role in expanding international diversification for investors seeking pharmaceutical and broader healthcare sector exposure via a receipt listed in their home market.